The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market
- 1 May 2020
- journal article
- letter
- Published by Elsevier BV in European Urology
- Vol. 77 (5), 660-661
- https://doi.org/10.1016/j.eururo.2019.11.019
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren's disease in 788 patients: the Austrian registerArchives of orthopaedic and trauma surgery, 2019
- Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical studyBJU International, 2018
- Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison AnalysisThe Journal of Sexual Medicine, 2018
- Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the LiteratureEuropean Urology, 2018
- Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm StudyThe Journal of Sexual Medicine, 2018
- Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 StudiesJournal of Urology, 2013
- Peyronie’s Disease Intervention Trials: Methodological Challenges and IssuesThe Journal of Sexual Medicine, 2009